Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?

Genmab (GMAB) shares jumped 10.7% after positive phase III trial data for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The result moves the drug into the frontline setting, a different patient population than the one the readout targets.

The earnings picture is mixed. The consensus EPS estimate for GMAB has been revised 8.7% higher over the past 30 days, a sign analysts were adjusting upward even before this move. Still, earnings are expected to fall 43.1% year-over-year, while revenues are forecast to grow 15.7%. That gap between a growing top line and shrinking profit is the key tension in the stock's fundamentals.

Zacks Research assigns GMAB a Rank #3 (Hold). That rating reflects estimate-revision trends, and it has not yet moved to a more bullish tier despite the upward EPS revisions. Interpretation: the market is treating the phase III result as a pipeline event, while the near-term earnings decline limits how far estimate momentum alone can justify the rally.